← All trials
NCT02735850
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2015
- Primary completion
- Feb 1, 2021
- Completion date
- Jun 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Maastricht UniversityLead sponsor
- Maastricht UniversityOverall official - principal investigator
- Netherlands Cancer InstituteCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Catholic University of Sacred Heart, RomeCollaborator
- Maastricht UniversityCollaborator
- University of CopenhagenCollaborator
- University of OxfordCollaborator
- Karolinska InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.